Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is C$5.49.
Separately, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th.
View Our Latest Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Down 3.4%
Shares of TSE MDP traded down C$0.10 during trading on Wednesday, hitting C$2.85. 80,844 shares of the company traded hands, compared to its average volume of 73,354. The firm has a market capitalization of C$63.81 million, a P/E ratio of 13.63 and a beta of 1.96. The company has a 50-day moving average price of C$2.92 and a 200-day moving average price of C$2.79. Medexus Pharmaceuticals has a 1 year low of C$1.71 and a 1 year high of C$5.56.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
See Also
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
